Targets › OTOF
4 programs from 4 companies in 4 trials: 3 Phase 1, 1 Phase 3; Neurology, Other; next expected readout Jul 2027.
Key calcium ion sensor involved in the Ca(2+)-triggered synaptic vesicle-plasma membrane fusion and in the control of neurotransmitter release at these output synapses. Interacts in a calcium-dependent manner to the presynaptic SNARE proteins at ribbon synapses of cochlear inner hair cells (IHCs) to trigger exocytosis of neurotransmitter. (UniProt, Q9HC10)
Open in Phaseline: the race on OTOF, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Eli Lilly | AAVAnc80-hOTOF Adeno-associated virus serotype delivering functional otoferlin gene | OTOF | Phase 3 | Sensorineural Hearing Loss, Bilateral | Oct 2028 |
| Sensorion | SENS-501 Gene therapy for OTOF mutations | OTOF | Phase 1 | OTOF Gene Mutation | Jul 2027 |
| Shanghai Euhearing Therapeutics | EHT102 Injection Dual-vector gene therapy for OTOF gene replacement | OTOF | Phase 1 | Treatment of Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF) | Jun 2028 |
| Regeneron Pharmaceuticals | DB-OTO AAV-mediated otoferlin gene delivery | OTOF | Phase 1 | Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF) | Feb 2029 |
Sensorineural Hearing Loss, Bilateral (1) Treatment of Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF) (1) Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF) (1) OTOF Gene Mutation (1)
other (2), small molecule (2)
Eli Lilly (1) Shanghai Euhearing Therapeutics (1) Regeneron Pharmaceuticals (1) Sensorion (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.